Expertise in
37
conditions

Dr. Yungpo B. Su

Oncology
Oncology Hematology West PC
450 E 23rd St, 
Fremont, NE 
Accepting New Patients
Expertise in
37
conditions
Oncology Hematology West PC
450 E 23rd St, 
Fremont, NE 

Overview

Yungpo Su is an Oncologist practicing medicine in Fremont, Nebraska.

Dr. Su is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Familial Pancreatic Cancer, Oral Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, and Familial Colorectal Cancer.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 6 clinical trials. Dr. Su is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NE

Fellowships

Cornell University Medical College, Internal Medicine - 2004
Memorial Sloan-Kettering Cancer Center, Medical Oncology - 2006

Hospital Affiliations

The Nebraska Methodist Hospital
Bryan Medical Center
Methodist Fremont Health
Chi Health Bergan Mercy
Methodist Jennie Edmundson

Languages Spoken

English
Mandarin
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

ONCOLOGY HEMATOLOGY WEST PC
450 E 23rd St, Fremont, NE 68025
Other Locations
ONCOLOGY HEMATOLOGY WEST PC
17201 Wright St, Suite 200, Omaha, NE 68130
ONCOLOGY HEMATOLOGY WEST PC
8303 Dodge St, Suite 250, Omaha, NE 68114
ONCOLOGY HEMATOLOGY WEST PC
7500 Mercy Rd, Omaha, NE 68124
ONCOLOGY HEMATOLOGY WEST PC
611 Fenwick Dr, Papillion, NE 68046

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drugs: Sorafenib, Everolimus
Study Phase: Phase 2
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Nivolumab
Study Phase: Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 5 Less Clinical Trials

10 Total Publications

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Journal: The New England journal of medicine
Published: June 02, 2025
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

The Urology Cancer Center

17607 Gold Plz, 
Omaha, NE 
 (21.7 miles away)
402-991-8468
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luke Nordquist is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Nordquist is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Prostatectomy. Dr. Nordquist is currently accepting new patients.

Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center

505 S 45th St, 
Omaha, NE 
 (29.8 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicole Shonka is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Shonka is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Shonka is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (29.8 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language, French
See accepted insurances
Accepting New Patients

Robert Bociek is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Bociek is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Bociek is currently accepting new patients.

Frequently Asked Questions about Dr. Yungpo B. Su

How do I make an appointment with Dr. Yungpo B. Su?

You can book an appointment with Dr. Yungpo B. Su by calling their office at 402-941-7030. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Yungpo B. Su a top-rated expert for Familial Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Yungpo B. Su is classified as an Distinguished expert for Familial Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Yungpo B. Su specialize in?

While Dr. Yungpo B. Su is a Oncology, they have specific expertise in Familial Pancreatic Cancer, Oral Squamous Cell Carcinoma, and Nasopharyngeal Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Yungpo B. Su participate in research or clinical trials?

Yes. Dr. Yungpo B. Su has published 10 articles and abstracts on conditions like Familial Pancreatic Cancer. You can view a list of Dr. Yungpo B. Su's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Yungpo B. Su accept my insurance?

Dr. Yungpo B. Su accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 402-941-7030 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Su's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 29 Advanced Conditions
    View All 116 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile